Peanut allergies can be life-threatening, but there’s hope on the horizon.
Oral immunotherapy, a method of gradually introducing small amounts of peanut allergen to desensitize individuals with peanut allergies, has been used by allergists for some time.
Now, a groundbreaking study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting introduces a novel approach to this treatment: specially formulated toothpaste.
The study demonstrates that this toothpaste can successfully deliver allergenic peanut proteins for oral mucosal immunotherapy (OMIT), providing a targeted and convenient way to desensitize individuals with peanut allergies.
A Toothpaste-Based Breakthrough
Dr. William Berger, an allergist and author of the study, explains, “OMIT uses a specially formulated toothpaste to deliver allergenic peanut proteins to areas of the oral cavity.”
Unlike traditional methods, OMIT offers precise delivery and straightforward administration, increasing the likelihood of patient adherence to the treatment regimen.
The Study Design
The study involved 32 adults between the ages of 18 and 55, all of whom had peanut allergies. Participants were randomly assigned in a 3:1 ratio to receive an escalating dose of INT301 (the toothpaste-based treatment) or a placebo.
To be eligible for the study, individuals had to meet specific criteria, including positive skin prick tests (SPT) and/or elevated specific peanut IgE (psIgE) levels, as well as failing an oral food challenge with ≤ 100 mg of peanut protein.
Ensuring Safety and Efficacy
Over the course of 48 weeks, the study closely monitored safety during the dose escalation and maintenance phases. Researchers also evaluated exploratory biomarkers, which are blood tests used to assess the immune system’s response to peanut allergen treatment.
Furthermore, oral food challenges were conducted to assess participants’ ability to tolerate peanut protein.
The study yielded promising results. Dr. Berger notes, “100% of those being treated with the toothpaste consistently tolerated the pre-specified protocol highest dose.”
Importantly, no moderate or severe systemic reactions occurred in the participants receiving the toothpaste treatment. Most adverse reactions were mild and localized, primarily causing oral itching.
Impressively, 97% of participants adhered to the treatment, with no dropouts due to the study medication.
A Safe and Convenient Option
OMIT using the specially formulated toothpaste appears to be a safe and convenient option for adults with peanut allergies. These findings support its continued development, particularly for pediatric use.
Immunologic responses to the treatment suggest that further evaluation is warranted, paving the way for potential advancements in peanut allergy management.
The success of this phase 1 trial has paved the way for additional long-term studies. These studies will further assess the toothpaste-based therapy’s ability to provide sustained protection against accidental peanut ingestion.
The toothpaste-based immunotherapy offers hope for individuals with peanut allergies, potentially improving their quality of life and reducing the risk of severe allergic reactions.
In conclusion, this innovative approach using specially formulated toothpaste represents a significant breakthrough in the treatment of peanut allergies.
It offers a safe, convenient, and potentially effective way to desensitize individuals, with the promise of long-term protection against peanut allergen exposure.
If you care about nutrition, please read studies that whole grain foods could help increase longevity, and vitamin D supplements strongly reduce cancer death.
For more information about nutrition, please see recent studies about natural coconut sugar that could help reduce blood pressure and artery stiffness, and whey and soy protein may reduce inflammation in older people.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
